Leerink analyst Mani Foroohar keeps an Outperform rating on Regenxbio (RGNX) after the company announced the FDA extended its review of clemidsogene lanparvovec for mucopolysaccharidosis II to February 8, 2026, from November 9, 2025. The extension follows submission of longer-term data for all patients in the pivotal study at the FDA’s request, the analyst tells investors in a research note. Leerink believes the extension is related as much to the recent turnover at the Center for Biologics Evaluation and Research than it is to specific review issues for Regenxbio. It says the delay is “not a needle mover” and should have a muted impact on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Strategic Developments and Partnerships Bolster RegenXBio’s Buy Rating Amid Regulatory Delay
- Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments
- FDA Extends Review for RegenXBio’s RGX-121 Therapy
- Regenxbio announces FDA review extension for RGX-121 BLA
- Regenxbio price target lowered to $17 from $21 at RBC Capital